- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02696928
Methylene Blue Against Vivax Malaria in Ethiopia (BlueAL)
Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial
Feasibility of methylene blue-based combination therapy in the radical treatment of adult patients with Plasmodium vivax malaria in Ethiopia: a randomised controlled pilot trial
Study rationale:
Elimination has become the goal of malaria programmes in an increasing number of endemic countries and regions. Primaquine (PQ) is the only registered drug for radical cure of Plasmodium vivax malaria. Prolonged PQ-based combination therapy carries safety concerns and resistance to chloroquine (CQ) and PQ is emerging. Methylene blue (MB) has recently been shown to be safe and effective in the treatment of Plasmodium falciparum malaria in West Africa. As there is evidence for MB probably being effective against the hypnozoites of Plasmodium vivax, MB-based drug regimens could be an alternative to PQ-based combination therapy in Plasmodium vivax malaria.
Study objectives:
The main objective of this trial is to study the feasibility of MB-based combination therapy in patients with uncomplicated P. vivax malaria in an endemic area of Ethiopia.
Study Overview
Status
Conditions
Detailed Description
The specific aims are (1) to test the feasibility and costs of methods and procedures for later use of MB-based combination therapy on a large scale, (2) to assess the safety of MB-based combination therapy, (3) to estimate the efficacy of MB-based combination therapy against malaria relapse, (4) to study the community acceptance of MB-based combination therapy, and (5) to strengthen the local capacity for malaria research and control in Jimma/Ethiopia.
Study design:
The study is designed as a pilot trial in adult patients with uncomplicated P. vivax malaria in Jimma, Ethiopia. Patients will be randomised to three treatment groups:
- Arthemeter/Lumefantrine (AL)
- AL-PQ, and
- AL-MB. Follow-up will be over a period of 6 months.
Study population:
Adult patients with uncomplicated P. vivax malaria (age ≥18 years) in Jimma/Ethiopia (G6PD deficient subjects are excluded) will become enrolled in the outpatient departments of the study centres. The sample size will be 33 per study arm, a total of 99 patients.
Study treatments:
- AL standard treatments twice daily (total of 80 mg/dose A plus 480 mg/dose L) over first three study days
- PQ 15 mg once daily for 14 days
- MB 780 mg once daily for 14 days Treatments will be 100% directly observed.
Study outcomes:
Outcome parameters will be on feasibility and costs (e.g. recruitment rates, retention rates, costs per patient), on safety parameters (e.g. haemoglobin development during follow-up, incidence of adverse events), on efficacy parameters (e.g. incidence of P. vivax relapse during follow-up, malaria recurrence-free efficacy until day 180), and on community acceptance (e.g. perceptions on blue urine) during follow-up.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- Uncomplicated P. vivax monoinfection (asexual parasite count >250/µl)
- Axillary temperature ≥ 37.5°C or history of fever during last 48 hours
- Ability to tolerate oral drug therapy
- Written informed consent of patient
- Permanent residence in the study area
Exclusion Criteria:
- Therapy with an antimalarial (e.g. CQ, amodiaquine, pyrimethamine-sulfadoxine, quinine, any ACT) or an antibiotic which is effective against malaria parasites (e.g. doxycyclin, clindamycin, CoTrim) during last three weeks
- Mixed malaria infection
- Clinical danger signals (e.g. unable to stand or to sit, unable to drink, repeated vomiting, convulsions) or signs and symptoms of severe malaria (according to WHO definition)
- Known other serious illnesses (e.g. cardiac, renal, hepatic, pulmonary disease, severe malnutrition, severe infectious diseases)
- G6PD deficiency (<60% activity, WHO classification 1-3)
- Patients with known allergy to one or more of the study drugs
- Hemoglobin value <7 g/dL
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Artemeter-Lumefantrine (combination therapy)
33 patients (standard of care) |
AL first 3 days
Other Names:
|
Active Comparator: Artemeter-Lumefantrine and Primaquine (combination therapy)
33 patients
|
AL first 3 days PQ next 14 days
Other Names:
|
Experimental: Artemeter-Lumefantrine and MB (combination therapy)
33 patients
|
AL first 3 days MB next 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study feasibility
Time Frame: 180 days
|
Patient recruitment rates
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of P. vivax
Time Frame: 180 days
|
Passive and active surveillance
|
180 days
|
Adverse events (AE) during total follow-up period
Time Frame: 180 days
|
Passive and active surveillance
|
180 days
|
Study costs
Time Frame: 180 days
|
Costs per patient
|
180 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Olaf Müller, Prof. Dr., Heidelberg University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UniHD007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vivax Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordMenzies School of Health ResearchCompletedUncomplicated Vivax MalariaAfghanistan, Ethiopia, Indonesia, Vietnam
-
Centers for Disease Control and PreventionTerminated
-
Menzies School of Health ResearchMinistry of Health, MalaysiaUnknownPlasmodium Vivax Malaria Without ComplicationMalaysia
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... and other collaboratorsRecruitingVivax Malaria | Malaria, Vivax | Plasmodium Vivax | Malaria RelapseCambodia, Ethiopia, Indonesia, Pakistan
-
Menzies School of Health ResearchUniversity of Melbourne; Curtin University; Addis Ababa University; Fundação de... and other collaboratorsNot yet recruitingVivax MalariaBrazil, Ethiopia, Indonesia, Papua New Guinea
-
University of OxfordCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompletedMalaria | Vivax MalariaPakistan
Clinical Trials on Artemeter-Lumefantrine (combination therapy)
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...Completed
-
London School of Hygiene and Tropical MedicineSave the ChildrenCompleted
-
Liverpool School of Tropical MedicineMalawi-Liverpool-Wellcome Trust Clinical Research Programme; National Malaria... and other collaboratorsUnknown
-
Centers for Disease Control and PreventionMinistry of Health, Brazil; Evandro Chagas National Institute of Infectious... and other collaboratorsCompleted
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; European Union; Kilimanjaro Christian Medical...Completed
-
London School of Hygiene and Tropical MedicineUniversity Medical Center Nijmegen; Centre national de recherche et de formation...Completed
-
JhpiegoUnited States Agency for International Development (USAID); Centers for Disease... and other collaboratorsCompleted
-
Papua New Guinea Institute of Medical ResearchNational Department of Health, Papua New Guinea; Australian Agency for International...CompletedParasitologically Confirmed; MalarialPapua New Guinea
-
University of Cape TownLondon School of Hygiene and Tropical MedicineCompletedHIV | MalariaSouth Africa
-
University of LiverpoolInfectious Diseases Institute, Makerere University College of Health Sciences and other collaboratorsRecruitingMalaria,FalciparumUganda